These two do the same job from opposite directions. truSculpt heats fat, CoolSculpting freezes it. truSculpt is monopolar radiofrequency. It holds the skin surface at around 44 to 45 degrees Celsius. CoolSculpting is contact cooling, with a target temperature down to minus 11 degrees. Both aim to kill fat cells, which the body then clears over weeks.
The sharpest practical difference is where each one is cleared to work. truSculpt iD's fat wording covers the abdomen and nothing else. The exact phrase is "reduction in circumference of the abdomen and non-invasive lipolysis (breakdown of fat) of the abdomen". It applies only to the 2 MHz setting on the 40 square centimetre handpiece. CoolSculpting's wording covers seven named regions, plus under the chin and jaw.
Do not confuse truSculpt iD with truSculpt flex. They share a brand, but they are different machines doing different things. truSculpt flex is electrical muscle stimulation. Its clearance is held by a different company, and it carries no fat wording at all. It covers only abdominal tone and strengthening, plus toning and firming of buttocks and thighs. If a clinic offers "truSculpt", ask which one.
Cutera markets truSculpt iD with an "average of 24% fat reduction", and that figure could not be traced to a named published study. The closest published number comes from a single-arm study of 12 people, with no control group. It found a 24 per cent drop in fat-layer thickness by ultrasound at 12 weeks. Nothing on the record says whether that is the source of the marketing figure.
The fat wording applies to the 40 square centimetre hands-free handpiece at 2 MHz. The massage attachment is a separate part with its own separate claim.
It was authorised through a De Novo request, DEN090002, decided 24 August 2010. That request created the FDA device category for cryolipolysis.
The FDA-reviewed study behind the clearance looked at tissue under a microscope. Biopsies taken at abdominoplasty showed fat cell death peaking at 30 days. It affected roughly 33 per cent of fat cells, from just under the skin down to about 1.5 cm. There was no damage at 3 cm.
Scavenger cells clear the dead cells over the following weeks. Nothing is heated, and nothing is removed on the day.
K180709, cleared 6 June 2018, and repeated in K221407 and K223110 in 2022. A 510(k) clearance means the FDA agreed the device is much the same as one already on the market. It is not a finding that the device works. Note also that truSculpt iD's cleared indication carries no body mass index limit, unlike several others in this class.
CoolSculpting Elite, K212707, cleared 5 November 2021. Under the chin and jaw are cleared separately, up to a body mass index of 46.2.
The clearance study did not measure fat thickness or circumference at all. It counted damaged cells in biopsies from 12 people, with a single follow-up visit. The published efficacy study also had 12 people, one arm and no control. It found 4.6 mm off the fat layer, or 24 per cent, at 12 weeks, with 10 of 12 above 20 per cent.
Blinded photo picking is the main endpoint in most CoolSculpting clearances. It is a spot-the-difference test, not a measurement of fat. The FDA's own pooled review inside K160259 put mean ultrasound reduction at 20.6 per cent, across a range of 10.3 to 25.5 per cent. An independent randomised split-body trial found about 14 per cent.
The applicators sit flat on the skin rather than pulling tissue into a cup. So it does not need a bulge to grip.
The vacuum cup needs something to draw in. That is why it suits a distinct bulge rather than a broad flat area.
In the 12-person clearance study, 11 of 12 had brief mild to moderate redness and swelling. It cleared in one to four hours. One person had mild pain lasting a day. Pain scores in the published efficacy study were 2 to 4 out of 10.
Delayed pain arriving a few days later is common. One review of 554 procedures found it lasted 3 to 11 days. Numbness beyond 12 weeks happened in 4 of 30 patients in the FDA-reviewed arm study.
The 15-minute figure comes from the maker and from clinics, not from a trial.
In the largest real-world review, covering 3,262 patients, the median was 4 cycles and 1 session per patient. The range ran from 1 to 177 cycles.
59 per cent of those reviewers rated it "Worth It".
Also 59 per cent "Worth It". CoolSculpting is priced per cycle rather than per session. That is why the reported totals spread so widely.
The evidence bases are not the same size: CoolSculpting has a De Novo authorisation and thirteen later clearances naming specific body areas. It also has an FDA-conducted pooled review of 4,792 treatments drawn from the published literature. truSculpt's fat clearance rests on a 12-person tissue study with a single follow-up visit. Those patients were already booked for an abdominoplasty, and neither fat thickness nor circumference was measured. The best published efficacy figure for it is also 12 people, one arm, no control group, in a journal with heavy industry involvement.
That is not an argument that heat does nothing. Cell death was documented under the microscope, and the depth at which it happened was mapped. It is an argument for reading the 24 per cent figure as what it is. It is an uncontrolled result in twelve people, not a number you can expect.
Cutera's product materials state an average of 24 per cent fat reduction, and that figure could not be tied to any named published study: A published study reports the same number. Taub and Bartholomeusz, in 2020, found a 4.6 mm drop in fat-layer thickness by ultrasound at 12 weeks, equal to 24 per cent. There were twelve people, each of whom had one 60-minute session across four areas. But no source connects the marketing figure to that paper. And the paper is a small single-arm study with no control group.
Read the percentage carefully in either case: It is a percentage of the thickness of a fat layer at one measuring point. It is not a percentage of body fat. It is not a percentage of the bulge, and it is not a percentage of body weight.
They sound like two versions of one product. They are not. truSculpt iD is radiofrequency, and its clearance names fat. truSculpt flex is electrical muscle stimulation delivered through contact electrodes. Its clearance is K212866, from 3 December 2022, and it is held by Johari Digital Healthcare Limited. It reads "improvement of abdominal tone, for strengthening of the abdominal muscles, for development of firmer abdomen" and "strengthening, toning and firming of buttocks and thighs". There is no fat or lipolysis wording anywhere in it.
A clinic offering "truSculpt" may mean either one. It matters. A muscle device and a fat device do not treat the same complaint, and neither can stand in for the other.
The FDA states it plainly on its non-invasive body contouring page, last updated 15 October 2025: "Non-invasive body contouring does not treat obesity or improve your health. It will not result in weight loss or contribute to the health benefits associated with weight loss." CoolSculpting's own safety information says the procedure is not a treatment for weight loss.
That framing comes from the regulator and from the manufacturers. It does not come from a professional society position statement. A pooled analysis of cryolipolysis studies found no real change in body weight: minus 1.81 kg, p = 0.09.
Ask which truSculpt machine the clinic owns, and which handpiece it will use: The fat wording applies to the 2 MHz setting on the 40 square centimetre handpiece, and to the abdomen. Treating any other area with this device sits outside what it is cleared for. That is legal for a clinician to do, but it is worth knowing before you agree to it.
Radiofrequency and implanted electronics are a standard problem: Tell your provider about a pacemaker, an implantable defibrillator, or any metal implant near the area. Ask to see the device's own instructions for use, and what they exclude.
For CoolSculpting, three blood disorders rule it out completely: They are cryoglobulinemia, cold agglutinin disease and paroxysmal cold hemoglobinuria. In all three, blood reacts badly to cold. Also disclose cold urticaria, Raynaud's disease, pernio or chilblains. Add any bleeding disorder or blood thinner, reduced feeling or poor circulation in the area, and any hernia in or next to the treatment site. Hernia appears on the FDA's risk list for this whole class, and on the maker's precaution list.
Fever or chills after treatment
Redness around a treated area that is visibly spreading hour by hour
Pus or discharge from treated skin
These are signs of a spreading infection and need urgent care the same day.
A firm, well-defined lump appears in a CoolSculpting-treated area two to six months later, above all if it matches the shape of the applicator
A blister, crust or open area appears on treated skin after a radiofrequency treatment
Redness or swelling after truSculpt is still there the next day rather than settling within a few hours
Numbness in a cooled area is still there after about three months
Pain in a treated area is rising rather than settling after the first two weeks
An area starts to look hollow or dented next to the other side
Paradoxical adipose hyperplasia is the reason the first item is there. After cryolipolysis, the treated area sometimes grows instead of shrinking. It becomes a painless, firm, clearly edged swelling, holding more fat than was there before. It does not clear up on its own, and correction means liposuction or an abdominoplasty. That surgery is usually put off for six to nine months, until the tissue softens. More cryolipolysis in the same area makes it worse.
How often it happens is genuinely unsettled, and the published estimates span roughly a hundredfold: The original 2014 case report calculated 0.0051 per cent, about 1 in 20,000 cycles. The maker's current safety information gives 1 to 10 per 10,000 treatments. The best-powered estimate is a 2025 meta-analysis of 28 studies and 13,078 patients. It pooled the rate at 0.22 per cent, about 1 in 455 patients. Its authors wrote that the incidence "appears to be higher than manufacturer reports". They also noted that only 4 of the 28 studies followed people for 16 weeks or longer, which is shorter than the period in which it usually shows up. A 2025 review of 18,203 cycles at one practice found 0.018 to 0.048 per cent per cycle. StatPearls reports about 0.91 per cent, or 1 in 110 treatments, from a 2020 review. Per-cycle and per-patient figures are not interchangeable.
This is a cryolipolysis complication. It has been reported once after a radiofrequency device. But there is no incidence figure for radiofrequency, and no case series.